Cytonus Therapeutics, Inc.

1:30 PM - 1:45 PM, Thursday, June 6, 2019 ・ Theater 1
Cytonus Therapeutics, Inc. is a early-stage biotechnology company spin out of the University of California, San Diego (UCSD) which has developed a novel Adoptive Cell Transfer (ACTs) platform dubbed Cargocyte™. Our technology utilizes a variety of enucleated cell lines (allogeneic or autologous) including Mesenchymal Stem Cells and immortalized cells that can carry a multiplicity of therapeutic payloads such as chemokines, cytokines, oncolytic viruses, gene-editing technologies, nanoparticles and small molecules. Our lead therapeutic product GM1215 will be engineered for our sentinel program targeting Pancreatic Adenocarcinoma.
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
Ohio
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
GM1215
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
CEO
Cytonus Therapeutics, Inc.